Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View More Conferences

2018 International Liver Cancer Association Annual Conference

Oncology Conference Multimedia
View more videos >>
Dr. Cheng on the Need For Biomarkers in HCC
Dr. Cheng on the Need For Biomarkers in HCC
Dr. Basu on Second-Line Therapy in HCC
Dr. Basu on Second-Line Therapy in HCC
Dr. Llovet on Combination Therapy in HCC
Dr. Llovet on Combination Therapy in HCC
Oncology Conference Articles
Immunotherapy Combos May Shape the Future of HCC Therapy
Immunotherapy Combos May Shape the Future of HCC Therapy
The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.
Sangro Says Immunotherapy May Be the Future of HCC Treatment
Sangro Says Immunotherapy May Be the Future of HCC Treatment
Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.
Regorafenib Sustains OS Benefit in RESORCE Trial Update
Regorafenib Sustains OS Benefit in RESORCE Trial Update
Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.
Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC
Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC
The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.
ILCA President Highlights Progress, Looks to the Future of HCC Treatment
ILCA President Highlights Progress, Looks to the Future of HCC Treatment
Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.
Second-Line Cabozantinib Proves Effective in HBV+ Liver Cancer
Second-Line Cabozantinib Proves Effective in HBV+ Liver Cancer
Cabozantinib improved survival as second-line therapy for patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection.
Atezolizumab Combo Promising as Frontline HCC Therapy
Atezolizumab Combo Promising as Frontline HCC Therapy
The combination of atezolizumab and bevacizumab demonstrated strong signals of efficacy with a tolerable safety profile as first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
Novel Agents Prompt Need for New Sequencing Strategies in HCC
Novel Agents Prompt Need for New Sequencing Strategies in HCC
The rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded the options for systemic treatments over the past 2 years, creating the need for new sequencing strategies.
Expert Explores Emerging Role of Personalized Medicine in HCC Treatment
Expert Explores Emerging Role of Personalized Medicine in HCC Treatment
Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.

Brought to you in part by Eisai

Publication Bottom Border
Border Publication
 
x